Shifting of Top-Selling Drugs: Semaglutide Surpasses Keytruda Novo Nordisk's financial report shows that in the first quarter of 2025, semaglutide achieved sales revenue of US$7.864 billion, while Merck's Keytruda achieved revenue of US$7.205 billion
Its global status is that of an investigational, research-only chemical
Optometrists should perform a baseline dilated comprehensive eye examination on patients who take these medications for any reason to determine their pre-existing level of DR and whether they have any risk factors for developing NAION
Additionally, BPC-157, by inhibiting the mRNA expression of inflammatory mediators (iNOS, IL-6, IFN, and TNF-), minimizes the risk of unwanted inflammatory conditions during postoperative recovery
Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology
Semaglutide is a prescription medication that helps support weight management by regulating appetite and promoting feelings of fullness